Patients with IPF and lung cancer: diagnosis and management

Τzouvelekis, Αrgyris; Spagnolo, Paolo; Bonella, Francesco; Vancheri, Carlo; Tzilas, Vasilios; Crestani, Bruno; Kreuter, Michael; Bouros, Demosthenes

doi:10.1016/s2213-2600(17)30478-2

Cited by 81 publications

(53 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lung cancer diagnosis is crucial for reducing morbidity and increasing the quality of life of patients (24,31,32). An early diagnosis of lung cancer may improve the administration of timely anticancer treatments, including surgery, chemoradiotherapy and immunotherapy, for patients with lung cancer, which can further improve the overall survival and progression-free survival (33)(34)(35). Clinically, PET/CT has been widely used for diagnosing human lung cancer and evaluating metastatic lesions (36).…”

Section: Discussionmentioning

confidence: 99%

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

et al. 2019

View full text Add to dashboard Cite

Positron emission tomography-computed tomography (PET/CT) is an efficient method for the diagnosis of various types of human cancer. Studies have demonstrated that Gd 2 O 3-doped carbon-11-choline (GdCho) can be used as a contrast nanoparticle for PET/CT in the diagnosis of patients with lung cancer. The aim of the present study was to evaluate the effect of GdCho-lenvatinib nanoparticles contrast-PET/CT (GdCho-Len-PET) in the diagnosis and treatment planning of a cohort of patients suspected of having lung cancer. The results of the present study demonstrated that GdCho-Len could be used as an efficient PET/CT contrast agent for the diagnosis of patients with lung cancer. GdCho-Len nanoparticles contrast agent exhibited a significantly improved longitudinal relaxivity compared with GdCho. The outcomes of the present study were that GdCho-Len-PET diagnosed 152 patients with lung cancer, whereas GdCho-PET diagnosed 130 patients with lung cancer among the 172 patients. GdCho-Len-PET presented with higher accuracy and sensitivity compared with GdCho-PET in diagnosing patients with lung cancer. All patients were further confirmed via histological analysis. GdCho-Len-PET contributed to the anticancer treatments in 56 out of 62 (90.3%) patients with lung cancer who were candidates for radiation therapy, 52 out of 57 (91.2%) patients with lung cancer undergoing adjuvant radiotherapy, and 13 out of 17 (76.5%) patients with lung cancer undergoing comprehensive therapy. Patients diagnosed using GdCho-Len-PET improved the survival of patients with lung cancer during a 420-day follow up. In conclusion, GdCho-Len-PET increased the diagnostic efficacy and had a significant effect on survival for patients with lung cancer, and may therefore serve as a reliable method for human cancer diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, despite a high risk for acute exacerbation and death from surgery and other treatments in this population, some patients may experience long-term survival after surgery, and this should be taken into consideration. 36,37 The mechanisms underlying the association between lung cancer and IPF have been the subject of several reviews. 38,39 Several common pathways between these two disorders have been reported, and include genetic and epigenetic changes, imbalances in cellular/tissue growth and migration, as well as changes in extracellular mediators.…”

Section: Cardiovascularmentioning

confidence: 99%

Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?

Alfaro

Cordeiro

2020

Ther Adv Respir Dis

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive parenchymal scarring, leading to dyspnoea, respiratory failure and premature death. Although IPF is confined to the lungs, the importance of IPF comorbidities such as pulmonary hypertension and ischaemic heart disease, lung cancer, emphysema/chronic obstructive pulmonary disease, gastroesophageal reflux, sleep apnoea and depression has been increasingly recognized. These comorbidities may be associated with increased mortality and significant loss of quality of life, so their identification and management are vital. The development of good-quality biomarkers could lead to numerous gains in the management of these patients. Biomarkers can be used for the identification of predisposed individuals, early diagnosis, assessment of prognosis, selection of best treatment and assessment of response to treatment. However, the role of biomarkers for IPF comorbidities is still quite limited, and mostly based on evidence coming from populations without IPF. The future development of new biomarker studies could be informed by those that have been studied independently for each of these conditions. For now, clinicians should be mostly attentive to clinical manifestations of IPF comorbidities, and use validated diagnostic methods for diagnosis. As research on biomarkers of most common diseases continues, it is expected that useful biomarkers are developed for these diseases and then validated for IPF populations. The reviews of this paper are available via the supplemental material section.

show abstract

“…Importantly, IPF is an age-related disease and thus presents with major comorbidities that significantly impact survival and quality of life (7)(8)(9). Besides the traditionally recognized comorbidities of lung cancer, pulmonary hypertension and gastroesophageal reflux disease (7,(10)(11)(12)(13), conditions related to the psychological impact of the disease have recently gained much of attention.…”

Section: Introductionmentioning

confidence: 99%